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INTRODUCTION 
Myocardial Infarction is one of the key components of cardiovascular 
disease burden all around the world. Coronary heart disease constitutes an 
immense public health problem.1 Coronary heart disease mortality has now 
decreased over the years, but the huge burden of its associated complications is on 
the rise. Effective utilization of multifaceted approaches (like drug discovery, 
clinical trials, and clinical policies) are necessary to reduce cardiac disease 
burden along with proper identification of patients with cardiovascular 
events, and also the incidence and outcome of such disease.  The epidemiology 
of Myocardial Infarction plays an immense role in proper investigation of such 
cardiovascular disease burden.2 
 
Majority of deaths from cardiac events, including coronary vascular 
disease and cerebro-vascular accidents occur in developing countries. Coronary 
artery disease has achieved epidemic proportion in India. Comparing the Indian 
subcontinent with other countries, coronary artery disease related mortality is still 
high with cardiac disease manifesting 10 years earlier than the rest of the world. 
The huge burden in Indian subcontinent may be attributed to its large population 
and high prevalence of cardiovascular risk factors which has emerged as a part of 
urbanization. As per the current scenario, cardiovascular death accounts for about 
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50% of total death, and it is predicted that, it may go up to 2/3rd of total 
death by 2020.3 
 
Considering this huge burden in our part of the world, it would be very 
helpful if a simple, common, biochemical investigation can act as prognostic 
predictor in those admitted with cardiac illness.  
 
Multiple molecules have been studied and used as prognostic predictors 
in Acute Myocardial Infarction. Purine metabolism results in the production 
of Uric Acid. Serum levels of uric acid is influenced by multiple factors like 
production and elimination rates, race, demography,  diet, habituations, organ 
failure and medications.4,5 On the molecular level, uric acid acts an 
antioxidant, and can result in the dysfunction of endothelial cells, proliferation 
of vascular smooth muscles and aggregation of platelets on vessel walls resulting 
in micro inflammation and tubulo-interstitial inflammation. Increased serum 
uric acid has been associated with increased incidence of metabolic syndrome, 
chronic kidney diseases, diabetes mellitus and cerebro-vascular accidents, proving 
uric acid as an important secondary marker of cardiovascular disease on the basis 
of pathophysiological and etiological processes, according to some researchers.6 
Another important factor supporting the use of Uric acid as a prognostic 
indicator of Myocardial infarction is that it is cheap to be tested. 
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Keeping all this in mind and the idea that uric acid can be used as 
an important yet independent prognostic predictor for worse outcomes, it 
would be helpful for earlier and accurate assessment of  Acute  Myocardial  
Infarction  going  in for  deterioration  and  for implementation of more effective 
and timely therapeutic strategies.  
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AIMS and OBJECTIVES 
 
1. To estimate the serum Uric acid levels in patients with acute myocardial 
infarction. 
2. To correlate the levels of serum uric acid with the severity of myocardial 
infarction as assessed by the Killip Classification, TIMI score and GRACE 
score. 
3. To correlate the levels of serum Uric acid with the two dimensional 
echocardiographic findings. 
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REVIEW OF LITERATURE 
HISTORY  
In the Central and Eastern parts of Europe, autopsies revealed 
atherosclerotic lesions that involved coronary arteries, based on studies by Adam 
Christian Thebesius - a well-known physician, who then used the term 
‘ossification of coronary arteries for the atherosclerotic lesions’. 
 
 
 
Giovanni B. Morgagni (1682-1771) who published his work, a 
collection of case reports in 1761 mentioned the symptomatology of angina 
pectoris and autopsy protocol showing ossification of aorta and its branches 
in such patients. Nicolas Rougnon deMagny (1727-1799) of France made the 
discovery of ischemic heart disease. Dr. William Heberden (1710-1801) also 
contributed to it.  
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(Figure - 2) 
 
Vilnius Jozef Chrzezonowicz, Jan Cenner and Andrzej Janikowski described 
‘angina pectoris’. All of them were of polish origin. First described case of a coronary 
embolism was by an Austrian physician, Adam Hummer in 1878, but it took nine 
years from that time to publish a paper regarding coronary artery embolism by 
another Polish physician Professor Edward-Sas-Korczynski (1844-1905). The concept of 
myocardial infarction, the pathological change associated with angina pectoris was 
suggested by Jozef Pawinski, father of Polish cardiology.  
 
(Figure – 3) 
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In the early 20th century, clinical diagnostic era found out its basis through 
the discovery of electrocardiogram by William Einthoven (in 1903).  Further 
detailing on myocardial infarction like complete occlusion or clogging of main 
coronary arteries were mentioned in the works of Zdzislaw Dmochowski and 
Walery Jaworski of Poland.  
 
 
(Figure – 4) 
The pioneers that built the backbone of the world of cardiology, thus can 
be inferred as the Polish Physicians.7 
Uric acid was discovered in 1776 by Carl Wilhelm Scheeleas a constituent 
of bladder stone hence he named it ‘uric acid’ or ‘bladder stone acid’. Uric acid 
was synthesized by Iwan Horbaczewski in the 1880s for the first time, by fusing 
glycine with urea by heating 3,3,3- tri-chloro-acetic acid. Though eighteenth 
century literature described uric acid, complete description of properties and 
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synthesis was achieved in 20th century. Uric acid is a yellowish white, tasteless, 
odourless substance in crystal or powder form, used for the commercial 
preparation of allantoin, alloxan, alloxautine, parabnic acid.8 
 
 
(Figure – 5) 
ATHEROSCLEROSIS 
 
Arteriosclerosis the term means “hardening of the arteries”. It is basically a 
common term for the thickening of the walls of arteries and thus loss of its elasticity. 
Atherosclerosis, is a Greek word rooted from words meaning “gruel” and 
“hardening”. 
 
9 
 
An atheromatous plaque consists of a raised lesion with a soft nucleus of lipid 
like cholesterol and its esters covered by a fibrous cap (Fig - 6). These plaques 
obstructs blood flow through these vessels, or it can rupture which will in turn lead 
to catastrophic events like obstructive vascular thrombosis, eventually leading to 
ischemic injury of the vessel walls. 
 
(Figure – 6  showing basic structure of an atherosclerotic plaque) 
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ACUTE MYOCARDIAL INFARCTION  
DEFINITION  
“The term Acute Myocardial infarction should be used when there is evidence of 
myocardial necrosis in a clinical setting constituent with acute myocardial 
ischaemia”. 
Criteria essential for the diagnosis of MYOCARDIAL INFARCTION. 

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Criteria for prior myocardial infarction  
 
 
Table – 1 : Criteria for prior MI (any one)9 
 
Types of Myocardial Infarction 
 
Table - 2 : Third Universal Definition of types of MI9 
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EPIDEMIOLOGY 
Several well established studies conduct heart disease surveillance to 
provide epidemiological data on myocardial infarction, names of which are 
described below. (Table – 3) 
 
Table – 3 studies providing epidemiological data on MI 
 
As a result of secondary prevention and adequate medical treatment, the 
coronary mortality rate has reduced and shows stable incidence trends.2 In the 
year 2003 in India, the village areas counted a CHD prevalence of 3-4% while 
urban areas showed 8-10%. 52% of the cardiovascular  
deaths occur under the age of 70 years, which implies a marked reduction in 
country’s working population, expected to be about 17.9 million years by 2030. 
Urbanization led to the intake of energy dense foods, decrease in physical 
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activity, increased psychosocial stress which promoted dysglycemia, 
hypertension and dyslipidemia, which are all risk factors for cardiovascular 
disease. This epidemic of coronary artery disease warrants urgent action like 
expanding public education, control of primordial and primary risk factors by 
population based interventions and effective preventive strategies.4 
 
The key results of South Asian components of the INTER-HEART study, a 
study based on reports from 52 countries all around the world, including India 
were,  
1. Average life span of patients with Acute Coronary Artery Disease in South-
Asian countries is 5-10 years lesser than western countries. 
2. Comparison of gender differences in Acute Myocardial infarction showed 
that males have 5-6 years lesser life span than females. 
3. Increased number of risk factors explains increased risk (86%) of Acute 
Myocardial Infarction. 
4. Abnormal Apo-B/Apo-A1 ratio and smoking increases the incidence of 
Acute Myocardial Infarction. 
5. Increased prevalence of AMI with Lower educational status. 
6. Alcohol consumption on a daily basis creates negative prognosis for Acute 
Myocardial Infarction.10 
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The inclusion criteria of this INTER-HEART study takes into account both 
types of MI, NSTEMI (Non-ST segment elevation myocardial infarction) and 
STEMI (ST segment elevation myocardial infarction).  
 
APPROACH TO ACUTE CORONARY SYNDROME 
 
Figure – 7: Approach to ACS 
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NON- ST ELEVATION MYOCARDIAL INFARCTION (NSTEMI)  
 
 
Patho-physiology 
Four processes which are responsible for Unstable Angina or Non-ST elevation MI, 
(1) Non-occlusive thrombosis superimposed on erosion, with NSTEMI caused by plaque 
rupture 
(2)  Dynamic obstruction like coronary spasm of Prinzmetal’s angina.  
(3) Progressive mechanical obstruction by advancing atherosclerosis or re-stenosis 
after percutaneous coronary intervention.  
(4) Situations demanding increased supply of Oxygen to Myocardium, as in 
tachycardia, anemia etc...  
 
 
 
 
Figure - 8: Lesions on Angiography – in NSTEMI 
5%
15%
30%
40%
10%
NSTEMI Patients - Lesions on Angiography
Left Main Coronary Artery Stenosis
Three Vessel disease
Two Vessel Disease
Single vessel Disease
No lesion On Angiography
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Angioscopy revealed thrombi, rich in platelet instead of thrombi rich in fibrin & 
cells like that seen in STEMI.  
Clinical Features  
Symptoms are sub-sternal or epigastric pain with radiation to neck, 
shoulder, arm, or angina/equivalents such as dyspnea or epigastric discomfort.  
Physical examination may reveal features of atherosclerosis, evidence of 
peripheral artery disease, anemia, thyroid disease and transient left ventricular 
failure.  
Investigations  
1. Electrocardiogram  
 
Figure 9: ECG Changes in NSTEMI 
T wave inversion > 0.3 mV 
ST segment depression 
Transient ST elevation 
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2. Cardiac Biomarkers 
CK-MB or Troponin will be elevated. 
 
The four major diagnostic tools are clinical history, ECG, Cardiac biomarkers 
and Stress testing or Coronary Imaging.  
Risk factor & Prognosis  
1-10% of patient with NSTEMI go in for early death (30 days), 3.5% for 
recurrent infarction.  The thrombolysis in Myocardial Infarction Scoring system 
identified seven independent risk factors. 
The Seven risk factors are: 
1.  Age > 65 years 
2. 3 or more CAD risk factors  
3. Documented CAD at catheterization  
4. Development of NSTEMI when patient is on Aspirin  
5. Anginal episodes, more than 2 in the preceding 24 hours  
6. ST segment elevation > 0.5 mm  
7. Increased levels of Cardiac biomarkers 
 
Other factors causing increased risk of CAD are 
1. T2DM, 
2. LVH, 
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3. Acute renal failure, 
4. Increased CRP and BNP 
(CRP – C-Reactive Peptide, BNP - brain natriuretic peptide) 
Treatment  
Medical treatment includes Nitrates, β-blockers or Calcium Channel 
Blockers, Antithrombotic therapy. CURE trial demonstrating 20% relative 
reduction in mortality with 1% increased risk of bleeding with double antiplatelet 
therapy.  
TRITON - TIMI 38 trial favored prasugrel as it can reduce the risk of 
cardiovascular death or stroke by 19% and stent thrombosis by 52% compare 
to clopidogrel. Heparins either unfractionated or low molecular weight remains 
the mainstay of therapy.  
 
Early Invasive Strategy - Class I - Indications (in high risk patients) are  
1. Recurrent angina at rest, despite treatment  
2. Elevated Troponin-T or Troponin-I  
3. New ST segment depression 
4. Symptoms of heart failure, mitral regurgitation  
5. Positive stress test  
6. Ejection fraction < 40% 
7. Decreased BP  
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8. Sustained Ventricular Tachycardia  
9. Per-cutaneous coronary intervention in less than six months  
10. Coronary Artery Bypass Graft kept before 
11. Higher vulnerability / risk score.  
 
The invasive strategy adopted is Coronary Arteriography followed by PCI 
or CABG according to the coronary anatomy. In long term, patient can be 
advised smoking cessation, daily exercise, weight reduction, blood pressure and 
glycemic control and lipid management along with anti-platelets, β-blockers, statins 
and ACE inhibitors.  
 
ST SEGMENT ELEVATION MYOCARDIAL INFARCTION  
Patho-physiology: 
STEMI occurs following the occlusion of a coronary artery by a 
thrombus which causes reduced coronary blood flow abruptly in a previously 
atherosclerosed vessel. The plaque surface gets disrupted promoting 
thrombogenesis. Minor incidences shows, STEMI can occur   due to other 
reasons like, coronary emboli causing occlusion of the affected vessel, vessel 
abnormities from birth genetically, spasm of the coronary arteries, and varied 
incidences of inflammatory disorders causing systemic effects.  
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In addition to common coronary risk factors, hyper coagulation state, 
collagen vascular disease, cocaine abuse, intra cardiac mass or thrombi 
producing coronary emboli are at increased risk of STEMI.  
Clinical Features 
Pain is a most common presenting complaint. There may be associated 
fatiguability, generalized body weakness, nauseating experiences, emesis, 
anxiousness and a feel of upcoming doom. Incidence of patients with STEMI 
without chest pain is greater if he is suffering from diabetes mellitus or 
immunosuppressant status in elderly. Most patients will be anxious and restless, 
show pallor associated with perspiration, cool extremities commonly. 
Patients with anterior infarction show evidence of sympathetic hyper activity 
like tachycardia, hypertension (in 1/4th of the cases) and approximately 50% of 
patients with inferior infarction prove evidence suggestive of increased 
parasympathetic hyperactivity like decreased heart rate and blood pressure 
leading to collapse. Signs of ventricular dysfunction like S3, S4 and paradoxically 
split S2 may be seen.  
Investigations  
The chief investigations are biomarkers, electrocardiogram & imaging.  
1. ECG  
The ECG manifestations of acute MI without LVH or LBBB are,  
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1. ST segment elevation>0.2 mV in males or > 0.15 mV in females in chest 
leads or > 0.1 mV in main leads.  
2. Tall T waves 
 
3. New ST depression of > 0.05 mV either horizontally or sloping down 
in 2 continuous leads  
And/or T inversion > 0.1 mV is 2 continuous leads with prominent R 
wave 
Or R/S ratio > 1.9 
 
Figure 10 showing ECG in acute STEMI 
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1. Cardiac biomarkers  
The preferred biomarkers are either Troponin I or Troponin T. It has high 
degree of absolute myocardial tissue specificity and sensitivity. It 
basically mirrors even the microscopic zones of Ischemic necrosis, usually 
expresses the measurement value more than 99 of a population used as reference. 
Blood samples are drawn on first assessment and 6-9 hours later. To establish 
the diagnosis, 1 elevated value above normal is required. If troponin is not 
available, CK-MB can be used.  
 
2. Cardiac Imaging  
Echocardiography is done to evaluate the thickness of the myocardium, 
motion of the myocardial walls at rest and its thickening. To detect areas of 
infarction, imaging studies like Cardiac Doppler, Contrast materials, Radio-
nucleotide imaging and Cardiac MRI are used.9 
 
Management 
The first 24 hours is very crucial as majority of deaths occur within that 
period due to Ventricular Fibrillation. Therefore pre hospital care in the form of 
symptom recognition, early medical attention like cardiac resuscitation and 
reperfusion therapy is highly essential.  
23 
 
If hypoxemia is present O2 should be administered at the rate of 2 to 4 litres per 
minute for first 6-12 hours.  
Drug treatment includes  
(1) Aspirin - for rapid inhibition of cyclo-oxygenase enzyme in platelets followed 
by reduction of thromboxane A2 levels. 
(2) Nitroglycerin (sublingual) - to control chest discomfort 
(Exceptions –SBP <90 mm of Hg, Infarction of right ventricular wall) 
(3) Morphine - Routinely administered for relief of pain which is often associated 
with STEMI by iv route in minimal doses (2-4 mg), at an interval of 5 min. 
(4) β-blockers - they are used intravenously to avoid re-infarction risk and 
ventricular fibrillation. Oral beta blockers are initiated within first 24 hrs in patients 
who do not have Heart failure, CHB, Known Asthmatics, or any interstitial lung 
diseases.11 
Next step in the management strategy is to decide between fibrinolysis 
and primary PCI. The primary aim is to confine the total span of ischemia 
within 120mins. If the patient cannot be transferred to a PCI capable hospital, 
fibrinolysis should be started within 30mins. If there is a contraindication for 
fibrinolysis or fibrinolysis became unsuccessful, an inter-hospital transfer 
should be considered, to a center where PCI is available, that too within 90 
min.12, 13 
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High risk patients include those in cardiogenic shock, hemodynamic or 
electrical instability and persistent ischemic symptoms. They are the prime 
candidates for rescue PCI after failed thrombolysis.  
 
Table 4 – Approach to the management of Acute coronary syndrome 
 
 
Complications  
 
Figure 11 – Complications of myocardial infarction 
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Patient with STEMI can go in for 
1. Ventricular dysfunction  
2. Pulmonary edema  
3. Cardiogenic shock  
4. Right ventricular infarction  
5. Arrhythmias  
6. Recurrent chest discomfort/ re infarction 
7. Pericarditis  
8. Thromboembolism,  
9. Left ventricular aneurysm.  
 
 
Post infarction strategies  
They include exercise stress testing before hospital discharge in stable 
patients, or 4-6 weeks after infarction in others. Coronary angiography, 
electrophysiological studies etc are advised accordingly. Secondary prevention 
is by anti-platelet drugs, ACE Inhibitors or ARB, or spironolactone in patients 
with Heart Failure, and warfarin in patients with  
high risk of embolism. Modification of risk factors promoting atherosclerosis is also 
essential for effective prevention of Myocardial Infarction. 
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PATHOLOGY OF MYOCARDIAL INFARCTION  
MI is the ischemic necrosis of cardiac cells. It can be categorized into 
coagulation or contraction band necrosis. Cell death begins after a definite interval 
of time (as it can be minimal as about 20 minutes as per animal models) and it may 
take up to 2-4 hours to go in for complete necrosis or even longer. It can be 
classified as Acute, Healing or Healed based on the pathogenesis of events. 
Acute infarction can be easily identified by the presence of 
polymorphonuclear leucocytes. Whereas Healing MI is characterized by 
mononuclear cells and fibroblasts along with absence of PMNLs. In a Healed MI, 
there is scar tissue and absence of cellular infiltration, which usually takes about 
5-6 weeks to form.14 
 
Temporal classification of STEMI 
 
Table-5 : Temporal classification of STEMI 
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PROGNOSTIC MARKERS OF ACUTE MYOCARDIAL INFARCTION 
1. Procalcitonin 
A study made in the department of Cardiovascular Science, University of 
Leicester, about relationship between Plasma Procalcitonin and Acute 
Myocardial Infarction showed that, when the plasma level of procalcitonin 
increases beyond the median level, it shows adverse outcomes in subjects 
with Acute Myocardial Infarction. It is also associated with LV dysfunction 
and remodeling post MI.16 
2. Heart rate variability, Arrhythmias and LV function 
Kansas medical university hospital studies made between 2002 to 2004, 
concluded that LVESV, atrial fibrillation/ flutter and ionotropic agent 
administration on day 1 are independent predictors of prognosis in Acute 
MI17 
3. Heart type Fatty Acid Binding Protein (H-FABP)  
Another study involving 1448 subjects with coronary artery disease 
was done. H-FABP level was measured from a single blood sample 
which showed patient negative for both H-FABP and Troponin I has lower 
risk, compared to those with positive H- FABP and negative troponin. The 
latter had higher risk of death.18 
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4. Circulatory phospholipase A2 
Circulatory phospholipase A2measured in patients with suspected acute 
coronary syndrome, help to distinguish between various causes of ST 
elevation in ECG. SPLA2 is significantly higher in ACS than other varied 
causes of ST elevation.19 
5. Cytokine - IFNr 
Cytokine – IFNr stimulates the breakdown of tryptophan into 
kynurenine. elevated K-T ratio is an index of heightened incidence of 
worse prognostic events in stable coronary artery disease.20 
6. Cell-free DNA levels 
Cell free DNA levels that originate from cell death & circulating in 
peripheral blood were significantly higher in patients with Acute 
Myocardial infarction and play a role in prognosis.21 
7. Serum Endoglin 
It is a proliferation and hypoxia inducible protein expressed in 
endothelial cells. An observational prospective study came to the inference 
that post AMI mortality can be predicted based on an early change in serum 
endoglin.22 
8. Cardiac Index and APACHE – II Scores 
Cardiac index and both initial and serial APACHE - II scores provide 
reliable prognostic information, whereas the serial BNP values were not 
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predictive of mortality associated with complicated AMI, patient in 
cardiogenic shock.23 
9. Circulating markers of collagen  
Circulating markers of collagen - turn over are of prognostic utility 
following Acute Myocardial Infarction. Among plasma levels of N-
terminal fragment of type1 collagen (PINP), carboxy terminal telopeptide 
of type 1 collagen (ICTP), matrix metalloproteinase (MMP-1) and tissue 
inhibitor of MMPS type 1 (TIMP-1). N terminal fragment of type 111 
collagen (PIIINP). ICTP is indicative of better prognosis in MI, either in 
Acute or in Chronic.24 
 
10. C- reactive protein  
C- reactive protein in acute myocardial infarction monitoring is highly 
helpful in  predicting the outcome along with uric acid and very low HDL 
levels. But it is not a specific index as it can rise in many other inflammatory 
conditions.25 
 
11. Creatine kinase 
Admission creatine kinase is a better prognostic predictor for a subsequent 
cardiac event, while Troponin T is a better predictor of mortality when we 
follow up for years. Together they do not improvepredictability.26 
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12. Growth differentiation factor-15 
Gdf-15 - a member of TGF-β family, has a prognostic role in AMI patients, 
and is useful for predicting death and heart failure. It shows increased 
levels during periods of ischemia and reperfusion.27 
 
13. N-terminal pro Brain Natriuretic peptide 
It can be used for risk stratification of NSTEMI and unstable angina. 
Among patients classified as low risk by an LVEF> 55%, negative 
Troponin T and a TIMI risk score of <4, NT pro BNP levels>331 ng/L 
predicted adverse clinical outcome.28 
 
14. Troponin T 
Troponin I and T are sensitive indicators of Acute Myocardial Infarction. But 
they can’t be considered as specific, as there are many conditions where the 
Troponin levels are falsely elevated. 
 
False elevation of Troponin  
1.  Cardiac contusion  
2.  Congestive heart failure  
3.  Aortic dissection  
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4.  Aortic valve disease  
5.  Hypertrophic Cardiomyopathy  
6.  Arrhythmias  
7.  Apical ballooning syndrome  
8.  Rhabdomyolysis with cardiac injury  
9.  Pulmonary embolism  
10. Kidney Failure 
11. Cerebro-vascular Accidents or SAH 
12. Drug toxicity  
13.Storage Disorders - Amyloidosis, Sarcoidosis 
14. Scleroderma, Haemochromatosis 
14. Inflammatory Myocarditis  
15. Drug toxicity  
16. Sepsis  
17. Burns  
18. Extreme exertion15 
 
 
SCORING SYSTEMS FOR MI 
 TIMI Score 
 GRACE Score 
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 PURSUIT Score 
 GESSI Score 
1. TIMI Risk Scoring  (Thrombolysis in Myocardial Infarction Score) 
In 1984, Eugene Braunwald made a study group in association with 
Brigham and Women’s Hospital and Harvard Medical School. This group 
was later called as TIMI group. It is used to predict the risk of death and also 
the ischemia associated problems in Unstable Angina or an NSTEMI.29 
 
Table 6 – TIMI risk score for NSTEMI 
Mortality Risk Calculation Using TIMI Score  
TIMI Score shows a mortality rate of more than 35% when the score crosses 
8/14. Hence the mortality associated with STEMI is higher compared to NSTEMI.30 
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Table 7 – TIMI risk score for STEMI 
 
 
Figure 12 – TIMI scores and mortality risk in STEMI and NSTEMI 
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2. GRACE Score 
 
Table 8 – components of GRACE score 
 
 
Sensitivity of both GRACE and TIMI are similar. (p = 0.79, not significant; while 
Specificity of GRACE score is significantly higher than that of TIMI Score 
 (p < 0.001) 
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Comparison between TIMI and GRACE Score 
 
Figure – 13 TIMI vs GRACE 
 
3. PURSUIT Score  
Risk Score is calculated with Age (0–14 points), Sex (1 if male), Chest pain (0–2 ), 
Heart Rate (0–5), SBP (0–2), ST-segment depression (1–3), and signs of heart failure 
(2–3). It was developed after a multinational RCT (Platelet Gp2b3a in Unstable 
angina: Receptor Suppression Using Integrilin Therapy). Patients are classed for risk 
for death at 30 days into low, intermediate and high risk. 
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KILLIP’S  CLASSIFICATION  
Killip and Kimball described 250 patients treated with AMI in a specialized ICU, 
who were managed based on risk stratification - reported improved mortality 
&morbidity in those patients (1967).31 
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URIC ACID  
When Cell death occurs, purine from the nucleic acids gets released and 
metabolized to form Uric acid, chemically, C5H4N4O3. Uric acid occurs widely in 
nature in the form of its salts, found in plants as well as in animals. It is a 
heterocyclic compound.  
Fig14 : Uric Acid Structure  
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Uric acid circulates as urate ion at normal arterial pH. Uric acid is not 
converted to allantoin so urates are regularly excreted in urine. The enzyme 
xanthine oxidase makes uric acid from xanthine and hypoxanthine, produced from 
Purines32.Uric acid production in human beings, uric acid is produced in the 
liver, along with dietary contribution.  
GMP, IMP, AMP →ultimately into guanine hypoxanthine→ xanthines 
Xanthine irreversibly oxidized to produce uric acid 
 
Figure 15  Uric acid pathway 
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Dietary sources  
Purine is highly present in different organic meals such as cod liveroil, breads, 
fishes, green leafy vegetables, and mushroom, fish like mackerel, herrings, 
sardines and mussels, yeast, bacon, beef, oatmeal, kidney beans, lentils etc are 
other sources of uric acid that is commonly available.33 
 
Excretion of uric acid  
Minor contribution in digestion of uric acid is by peroxidases and catalases. 
Elimination of uric acid in mainly through the GIT and kidneys. 1/3rd of total uric 
acid in digested by intestinal uricolysis.34 Two thirds is via the kidney. The 
transporters were URAT1 transporter (found only in proximal renal tubule 
inhibited by lactate and ketone bodies)35. GLUT9 -reabsorbs urate into 
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circulation. GLUT9 was previously identified as fructose transporter. 
Probenacid& benzo-bromarone inhibits these transporters.33  
Normal uric acid levels vary in sex and also show day to day and seasonal 
variations.  
Adult men  : 2 to 7.5 mg/dl 
Adult women : 2 to 6.5 mg/dl.  
 
In Early months of pregnancy, uric acid declined by 1/3rd; but by term the level 
rises to non-pregnant level. 
Men > 40 yrs:  2 to 8.5 mg/dl 
Women > 40 yrs:  2 to 8.0 mg/dl & 
There will be a rise in relation to menopause. 
 
The normal level of uric acid in urine will be 250-750 mg over 1 day period. 
Reference values need to be checked before each time we go in for Uric acid 
testing.  
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Increased levels of uric acid/ Hyperuricemia Seen with, 
Due to urate super saturation / 20 to decreased excretion, over production.  
 
Table 10 – causes of Hyperuricemia 
 
Decreased levels of serum uric acid/ Hypouricemia seen with, 
Occurs due to decreased production or increased excretion.  
1.  Transporter defect - familial renal hypouricemia 
2.  Fanconi syndrome  
3.  SIADH - volume expansion  
4.  Hodgkin’s lymphoma  
5.  Cerebral salt wasting - intracranial disease  
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6.  Vitamin C can reduce blood uric acid level37  
7.  Cherry juice - has shown to reduce uric acid when given to marathon runners.  
8.  Xanthine oxidase deficiency, purine nucleoside phosphorylase deficiency 
 
Uric acid and genetics  
The serum uric acid level in siblings of gouty patient was higher than siblings of 
controls. These observations were confirmed by the study of black foot and Pima 
Indians. The frequency distribution of uric acid is Gaussian/normal in 
general population.38  
In the study of 6000 subjects from Tecumseh community health study 
showed  multi  factorial  inheritance  with  additive  gene  action  interacting  
with environmental factors to produce serum uric acid phenotype.39  
 
URIC ACID AND DRUGS  
Drugs that causes Hyperuricemia: 
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Drugs that causes Hypouricemia: 
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Uric acid and oxidative stress  
When Uric Acid is synthesized, there is production of ROS leading to 
increased vascular oxidative stress.40 Xanthine oxido reductase, is a hepatic 
enzyme, which catalyse uric acid, produce ROS and damage the nucleic acids. 
XOR can be interchanged into two different forms XO- Xanthine oxidase, 
XDH -Xanthine dehydrogenase.  XO cannot reduce NAD+, unlike XDH, XO 
prefers molecular oxygen.41  
 
Allopurinol, a xanthine oxidase inhibitor, decrease uric acid levels and is 
beneficial by  
1) Decreasing ROS,  
2) Myocardial contraction is enhanced due to restoration of sensitization to 
calcium and its response to β adrenergic receptors,  
3) Preventing xanthine oxidase mediated intermittent hypoxia induced 
vasculardysfunction.42  
 
Uric acid as antioxidant  
Uric acid is an effective scavenger of all the free radicles produced, and also a 
chelator of ions of may minerals especially transitional metals. Which in turn 
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gets converted to inactive or less active forms.43These ideas are supported by both 
invitro and invivo studies44 . 
 
Urate act as antioxidant by  
1.  Reducing Lipid Peroxidation & Preventing RBC Aging,  
2.  A Scavenger of Singlet Oxygen and Hydroxyl Radicals.46  
3.  Scavenger of Oxo-Heme Oxidants. Plasma Urate Levels Are Higher than 
ascorbate making it a major antioxidant .47  
 
Uric acid and metabolic syndrome  
Metabolic syndrome is a group of diseases or disease risk factors, a like insulin 
resistance, hypertension, glucose intolerance, elevated triglycerides and HDL 
levels is a major public health problem.48 
Recent evidence suggest that uric acid may have a role in metabolic syndrome 
pathogenesis49and decreasing uric acid levels can reverse the features of MetS. 
Hyperuricemia is associated with android type obesity, not the gynoid type. 
Study done among the sumo wrestlers and Tecumsech community health  
study showed definite association between elevated serum uric acid and 
obesity.50  
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Molecular explanation for association between hyperuremia and MetS is high 
dietary carbohydrate intake (especially fructose or sucrose). In initial stages of 
obesity, elevated   plasma fatty acids are responsible for the increase in uric acid 
levels. Fructose enters hepatocytes, metabolized  by  fructokinase,  generates  
uric  acid  at  the  same  time  increase biosynthesis of TG, VLDL excretion and 
LDL over production.51  
 
Uric acid and hypertension  
Progetto hypertension Umbria MonitoraggioAmbulatoriale (PIUMA) study - 
PIUMA database was analysed to assess the association of serum uric acid and 
hypertension. Uric acid is bound for 5% of plasma proteins, freely filtered at the 
glomerulus, 99% reabsorbed in the proximal tubule and majority are reabsorbed. 
Thus a direct association exists between serum uric acid and renal vascular 
resistance, probably linking systemic hypertension and hyperuricemia.52 Animal 
models suggest endothelial dysfunction, reduction in nitric oxide levels, 
activation of RAAS and vascular smooth muscle proliferation as causes of 
hypertension in hyperuricemia. The more impaired the kidney function, the more 
the level of serum uric acid along with impaired blood pressure control.53 Moreover 
factors responsible for oxidative stress, polymorphic changes of transporters 
achieved genetically and functionally also needs consideration.  
 
47 
 
Uric acid and diabetes mellitus  
Lower serum uric acid was found in diabetics, higher levels in pre-diabetics 
compared to non-diabetic subjects.54  Hyperuricemia is a function of decreased 
renal function. The positive association between hyperglycemia of 8mmol/l (upto 
8mmol/l) is not dependent on BMI, alcohol intake, gout or diuretic treatment of 
hypertension and it probably reflects the interaction between glucose and purine 
metabolism, via the phosphorylation of glucose to glucose-6-phosphate.55 
Diabetes and non diabetics with a blood sugar level more than 8 mmol/l showed 
lower uric acid level, thus an effect of hyperglycemia rather than the use of oral 
anti-diabetic drugs.  
Hyperuricemia is presumed to be a consequence of insulin resistance rather than 
its precursor. When considered as a risk factor for diabetes mellitus, will be 
helpful if we can add uric acid lowering drugs in asymptomatic 
hyperuricemia, reducing the chance of type 2 diabetes mellitus.56  
 
Serum uric acid and Cancer  
Uric  acid  is  potentially  more  important  as  an  antioxidant  in  normal 
physiology. A positive association was detected between antecedent serum uric 
acid and subsequent development of prostate cancer within an interval of 10-15 
years but not with any other cancer site.57Hialt and Fireman found no relation of 
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uric acid in the blood with cancer prevalence after adjustment for age, race, 
education, tobacco consumption, alcoholism, and BMI.58  
Serum uric acid in smokers  
Cigarette smoke a source of oxidative stress on chronic exposure lead to low uric 
acid levels in smokers, when arranged excluding other risk factors. As the 
reduction in uric acid levels is proportional to smoking status and predispose 
to cardiovascular disease, the study recommends to quit smoking & introduce uric 
acid estimation as a routine test.59  
 
Serum uric acid and neurological disease  
Hypouricemia produces reduced free radical scavenging capacity of the 
body like peroxynitrate which in turn can produce cell damage. This is how 
uric acid acts as a neuro-protectant. Moreover astroglia must be present for uric 
acid to act. Uric acid acts on astroglia and up-regulate  EAAT-1, a glutamate 
transporter thereby protect spinal cord. Thus an astroglia mediated mechanism is 
behind the neuroprotection by uric acid.60  
 
SUA and Gout 
Monosodium urate crystal deposition leads to a painful rheumatic disease 
called gout. When concentration of uric acid is above 380 µ mol/L or 6.8 mg/dl it 
will precipitate. Disease is more common in men, as hyperuricemia can produce 
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gout, even low levels of serum uric acid can cause gout . gout can be due to 
purine rich diet, diuretic therapy, alcoholism and metabolic syndrome. Gout can 
be classified as primary (if no identifiable cause is present) or secondary. 
Treatment of gout includes lifestyle modification, nutrition, uric acid lowering 
drugs, like - xanthine oxidase inhibitors, uricosurics, uricase agents.61  
The different stages of gout includes 
 
SUA and Heart Failure  
Serum uric acid levels are elevated in patients with congestive heart failure, 
because of 1) parallel worsening renal function, 2) over protection of uric acid, 
3) restricted sodium intake and use of diuretics. Thus the use of diuretics in patient 
with heart failure, will increase SUA, and thereby plasma UA mediated 
antioxidant capacity, making diuretics beneficial in CHF prognosis.62  
 
 
 
50 
 
SUA and Renal diseases  
Very high levels of uric acid can produce renal insufficiency which rapidly 
progressive.   More   prolonged   form   of   hyperuricemia   leads   to   a   chronic 
tubule interstitial   disorder -   gouty   nephropathy.   Hyperuricemia   can   lead   
to nephrolithiasis too.63 
 
Regarding Hyperuricemia & renal diseases the features include  
1) Intrarenal crystal deposition,  
2) vasoactive & pro inflammatory effects64,  
3) Renal disease progression, 
4) male gender affected more65,  
5) hypertension, proteinuria65, renal dysfunction, vascular disease and 
progressive renal scaring,  
6) activation of RAAS and COX - 2 system.  
 
Uric acid nephropathy - can be oliguric or anuric, due to over production or 
under excretion of uric acid with serum levels >15 mg/dl.     The Uric Acid to 
S. Creatinine ratio   is >1 (0.6-0.7 in other AKIS).   Associated   features  are  
hyperkalemia,  hypocalcemia and hyperphosphatemia. Acute nephropathy is 
treated with I/V hydration, allopurinol or rasburicase.  
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If chronic nephropathy-uric acid crystal deposits in the medullary interstitium, 
results in chronic inflammation, interstitial fibrosis and chronic kidney diseases. 
If UA>9 with creatinine <1.5, UA > 10 with serum creatinine 5- 20, UA > 12 
with advanced renal failure chronic nephropathy can be suspected in CKD patients. 
  
Familial juvenile hyperuricemic nephropathy (MCKD type 2) 
It is an autosomal dominant inherited disease with gout and progressive renal 
impairment.  
 
 LITERATURE SUPPORTING THE STUDY 
 
In low risk group population of CVD; SUA is a relatively reliable predictor, 
but it gains high significance in high risk groups.66   Independent  association 
of uric acid with severity of atherosclerotic plaque in coronary vessels, has 
been attained in a cross sectional study of Turkish patients. Korean studies using 
angiography supported this association of SUA with non-modifiable risk factors of 
atherosclerosis.61   
Uric acid and acute MI 
1. In a retrospective study done in a hospital in Croatia, higher in-hospital 
mortality as well as thirty days mortality was observed in patients with 
higher serum uric acid levels, the study population being patients with acute 
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myocardial infarction, who presented within 48 hours of onset of symptoms. 
The long term survival was also worse in this group. Confounding factors 
were not found between SUA levels and myocardial infarction. Elevated 
creatinine value has also been found to be a good predictor of deaths 
following acute MI 67. 
2. Cross sectional study among Chinese males revealed that hyperuricemia 
causes elevated blood pressure and stiffness of arterial vessels68. Contrary to 
this, a study done in Korea suggests that there is no correlation between SUA 
levels and arterial wall pliability. The index that was used to assess the 
association between hyperuricemia and arterial stiffness was brachial-ankle 
pulse wave velocity. The proposed mechanism for the same in 
hyperuricemia, is the production of superoxide radicals and oxidative stress, 
causing the development and progression of stiffness of vessels.69 
 
3. A descriptive analytic research with non-random sampling in Zanjan Behesti 
Hospital in 2001, to assess the relationship between serum uric acid levels 
and AMI- concluded that: 
 (1) uric acid levels increase with age, no change with sex. 
   (2)a positive correlation exists between hyperuricemia and hypertension. 
    (3) no meaningful relationship between smoking or diabetes mellitus with 
serum uric acid.70 
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       4.  In Beijing, China 502 patients with STEMI were    studied to assess uric acid 
levels. Moreover serum lipid level and echocardiography data in hospital MACE 
were compared between hyperuricemia and non hyperuricemia. It was concluded 
that there is a positive correlation between SUA and triglyceride level, but it was not 
related to the severity of CAD.STEMI  patients with elevated SUA have higher 
incidence of systolic and diastolic dysfunction and more major adverse 
cardiovascular events (MACE) while in hospital.71 
 
5. Rotterdam study, which was a large prospective population based study, included 
4385 participants who, at the beginning of the study, were more than 55 years and 
free from CAD and stroke. They were followed up until January 2002 and the study 
revealed that SUA is a strong risk factor for MI and stroke.72 
 
6. In India, a study done in Seth GS hospital and KEM Mumbai assessed the close 
correlation between SUA levels and Killips classification in acute MI in 100 
patients, by measuring serum uric acid level on days 0,3 and 7. The conclusion were: 
(1) high SUA concentration in patients with MI on admission day and in patients 
with history of MI in the past. 
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(2) high SUA in patients with higher Killip class on all 3 days  
(3) Killip class and uric acid combined together,is a good predictor of mortality in 
acute MI.73 
7. Using Japanese acute coronary syndrome database, assessment of 1124 patients, 
who were hospitalised within 48 hours of MI, was done. Conclusions were as 
follows: 
(1) there is a close relation between SUA and Killips class. 
(2) SUA levels, killips class, peak CPK levels and age had significant predictive 
value of long term mortality. 
(3) SUA level is a good indicator for predicting adverse cardiac events in the future. 
Together with Killips class , it forms a good mortality predictor.74 
 
8. Framingham heart study was done to assess the relation of uric acid to incident 
CAD and death and it concluded that : 
(1) there is no causal role for uric acid in the development of CAD or death due to 
cardiovascular disease . 
(2) any apparent association could be attributed to the association of SUA with other 
risk factors 
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METHODOLOGY 
 
MATERIALS AND METHODS: 
Study design- prospective non interventional observational study 
Study setting- medical ICU, CCU and internal medicine wards of GMKMCH Salem. 
Duration of study – 100 consecutive cases of 2015- 2017. 
INCLUSION CRITERIA: 
 Age>18 years 
 ST Elevation Myocardial infarction 
 Non ST Elevation Myocardial infarction 
EXCLUSION CRITERIA: 
 Chronic kidney disease 
 Patients with prior myocardial infarction 
 Gout 
 Hematological malignancy 
 Patients on drugs like salicylate, ethambutol, pyrazinamide 
SAMPLE SIZE: 
100, out of which 55 STEMI and 45 NSTEMI were included. 
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PROCEDURE IN DETAIL: 
The study was conducted in 100 cases of acute myocardial infarction patients 
admitted to our hospital. Patients are selected according to inclusion and exclusion 
criteria from internal medicine and cardiology departments of Government Mohan 
Kumaramangalam Medical College Hospital. Diagnosis of myocardial infarction is 
based on chest pain>20 minutes, ECG changes and elevation of cardiac biomarkers( 
two out of three). Detailed history and physical examination with special reference 
to Killip classification were carried out. Patients were followed up for a period of 7 
days or discharge ,whichever is earlier. Uric acid values were measured on days 0 
and 3, and other necessary values for exclusion were collected on first day of 
admission, and mortality/morbidity rates calculated in the first week of admission. 
A venous blood sample was collected to measure uric acid by venepuncture, 
preferably fasting for the last 4 hours, unless told otherwise. Uric acid was measured 
using autoanalyser, using the modified Trinder technique in our clinical 
biochemistry laboratory ,with value>8mg/dl considered as hyperuricemia. Diabetes 
was diagnosed according to ADA criteria or if patient is on treatment with oral 
hypoglycemic agents or insulin. Hypertension was diagnosed by SBP>140 and 
DBP> 90, average of two readings taken. Smoking at least one cigarette per day, for 
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everyday during the year was considered as current smoker. Cardiac biomarker used 
for study was Troponin T. 
STATISICAL ANALYSIS 
The study design was a prospective non interventional observational study. All data 
collected were noted using a structured proforma, including the investigations. Data 
was analysed using statistical package and SPSS structured software to find out the 
significance of serum uric acid as prognostic marker in myocardial infarction. 
FUNDING AGENCY: none. 
ETHICAL CONCERNS: as per the institution protocol. 
CONSENT: informed consent was taken as per standard procedure that is followed 
in the institution. 
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RESULTS and OBSERVATIONS 
This was a prospective, observational and non interventional study. The study 
population had 100 subjects. 
1. AGE DISTRIBUTION  
The average age of the study group was 57.16 years. 36% of the patients belonged 
to the age group between 51 to 60 years. The age of the subjects ranged from as low 
as 34 years to as high as 80 years. 
TABLE – 11 SHOWING AGE DISTRIBUTION IN THE STUDY POPULATION  
AGE Number of Patients (n) Percentage ( n%) 
31 – 40 years 6 6 % 
41 – 50 years 23 23 % 
51 – 60 years 36 36 % 
61 – 70 years 24 24 % 
71 – 80 years 11 11 % 
CHART – 1 BAR GRAPH showing AGE DISTRIBUTION OF THE STUDY POPULATION 
 
6
23
36
24
11
31 – 40 YEARS 41 – 50 YEARS 51 – 60 YEARS 61 – 70 YEARS 71 – 80 YEARS
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
Age Groups
AGE Distribution
59 
 
2. GENDER DISTRIBUTION 
Among the 100 subjects, there were 66 males and 34 females 
TABLE 12 – GENDER DISTRIBUTION OF THE STUDY POPULATION 
SEX Number of patients (n) Percentage (n%) 
Male 66 66% 
Female 34 34% 
CHART 2 – GENDER DISTRIBUTION OF THE STUDY POPULATION 
 
 
TABLE 13 – AGE and GENDER distribution 
AGE Males Females 
31 – 40 years 4 2 
41 – 50 years 15 8 
51 – 60 years 24 12 
61 – 70 years 17 7 
71 – 80 years 6 5 
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CHART 3 – BAR GRAPH showing AGE and GENDER CORELATION IN THE 
STUDY POPULATION 
 
There is a predominance of males in all the age subgroups in the study. 
3.  TYPE OF MYOCARDIAL INFARCTION 
There were 45 cases of NSTEMI and 55 cases of STEMI in the study population. 
CHART 4 : PIE CHART showing TYPE OF MYOCARDIAL INFARCTION 
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4. MORTALITY STATISTICS 
9 deaths occurred in the study group of 100 patients. 8 patients had died of ST 
elevation MI and 1 patient died of Non ST elevation MI. Out of the 9 deaths that 
occurred, 6 were males and 3 were females. χ2 value was 0.965 and this was not 
found to be statistically significant. Most of deaths occurred in the age group 50 to 
70 years (77.78%) 
CHART 5 : MORTALITY IN THE STUDY GROUP 
 
TABLE 14 : MORTALITY IN THE STUDY POPULATION 
 Number of 
survived patients 
Number of 
patients died (n) 
Percentage of 
mortality (n %) 
MALES 60 6 10% 
FEMALES 31 3 9.68% 
9
91
Doughnut showing Mortality statistics in the study population
deaths alive
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CHART 6 : BAR Graph GENDER DISTRIBUTION AND MORTALITY 
 
TABLE 15. AGE RANGE DISTRIBUTION WITH MORTALITY 
    Mortality 
Total     No Yes 
Agerange 31 - 40 yrs 6 0 6 
41 - 50 yrs 22 1 23 
51 - 60 yrs 33 3 36 
61 - 70 yrs 20 4 24 
71 - 80 yrs 10 1 11 
Total 91 9 100 
χ2 value was 0.567 and the value was not statistically significant. 
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CHART 7 : BAR GRAPH showing AGE DISTRIBUTION WITH MORTALITY 
 
5. TROPONIN VALUE DISTRIBUTION 
54 % of the study group had high levels of troponin and this high values were seen 
in all 9 cases of myocardial infarction that died. The p value as per fisher’s exact 
test was 0.003 indicating that the result is statistically highly significant. 
 
TABLE 16 : TROPONIN ELEVATION WITH MORTALITY 
  Mortality 
Total   No Yes 
Troponin HIGH 45 9 54 
LOW 46 0 46 
Total 91 9 100 
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CHART 8: TROPONIN ASSOCIATION WITH MORTALITY 
 
6. KILLIP CLASS and URIC ACID LEVEL DISTRIBUTION  
TABLE 17 S. URIC ACID CORRELATION WITH KILLIP CLASS 
  Uric Acid Level (mg/dl) Total 
  3.1 - 5.0 5.1 - 7.0 7.1 - 9.0 > 9 
Killip 
Class 
I 8 28 4 0 40 
II 3 5 23 2 33 
III 0 0 5 13 18 
IV 0 0 0 9 9 
Total 11 33 32 24 100 
 
40 patients belonged to killip class 1. 33 patients were in killip class 2 with 18 
patients in killip class 3 and 9 patients in killip class 4 at the time of presentation. 
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Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 111.525a 9 .0005 
Likelihood Ratio 116.663 9 .000 
 
CHART 9 -  SERUM URIC ACID CORRELATION WITH KILLIP CLASS 
 
24 patients had serum uric acid levels > 9mg/dl and 91.6 % belonged to killip classes 
3 and 4.The  χ2 value was 0.0005 and is thus highly significant statistically. 
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7. HYPERURICEMIA and MORTALITY CORRELATION 
The proportion of hyperuricemics in the study population was 59%.  
Table 18 Showing Mortality Distribution According To S.Uric Acid Levels 
  Mortality 
Total   No Yes 
Uric 
acid 
levels 
Normal 
 
41 0 41 
Hyperuricemic 50 9 59 
Total 91 9 100 
    
 
Chart 10 showing proportion of Hyperuricemia in study population 
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Chart 11 - Mortality Distribution According To S. Uric Acid Levels 
 
The presence of hyperuricemia in the patients that died was 100%. 41% had normal 
serum uric acid levels and there were no deaths noted in the subgroup. 
 
8. KILLIP CLASS DISTRIBUTION AND HYPERURICEMIA 
Almost all individuals in Killip classes 3 and 4 had Hyperuricemia (96.3%)  
Table 19 – distribution of Hyperuricemia in various Killip classes 
  Serum Uric acid Level 
Total   Normal Hyperuricemic 
Killip 
Class 
I 35 5 40 
II 5 28 33 
III 1 17 18 
IV 0 9 9 
Total 41 59 100 
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Chart 12 – distribution of Hyperuricemia in various Killip classes 
 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 60.472a 3 .0005 
The p value was 0.0005 indicating that the result is highly significant 
Chart 13 Distribution of hyperuricemics in various Killip classes 
 
Among the hyperuricemic individuals (n =59) , 5 belonged to killip class 1, 28 
belonged to class II, 17 belonged to killip class 3 and 9 individuals were in killip 
class IV. 
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9. KILLIP CLASS AND MEAN SERUM URIC ACID LEVELS 
The Mean serum acid level in the study population was 7.57 +/- 2.31 mg/dl. Mean 
serum uric acid levels rose linearly with killip class. The mean serum uric level in 
killip classes 3 and 4 were 9.72 and 12.46 respectively. This indicates that serum 
uric acid levels correlated with the severity of myocardial infarction as assessed by 
killip classification. ANOVA test was utilized in the analysis and the sigma value 
was 0.0005 indicating very high significance. 
Table 20 . Killip class and mean serum uric acid levels 
Killip Class 
Number of 
patients 
(n) 
Mean 
Serum Uric 
Acid Levels 
Standard 
Deviation 
Standard. 
Error 
I 40 5.68 0.96 0.15 
II 33 7.36 1.11 0.19 
III 18 9.72 0.85 0.20 
IV 9 12.46 0.35 0.12 
Total 100 7.57 2.31 0.23 
  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 
442.525 3 147.508 158.832 .0005 
Within 
Groups 
89.156 96 .929     
Total 531.682 99       
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CHART 14 Mean serum uric acid levels in various Killip classes 
 
 
10. KILLIP CLASS and MEAN URIC ACID in HYPERURICEMIA 
The mean uric acid levels in hyperuricemic individuals is 8.96 +/-1.9 mg/dl. The 
mean serum acid levels in the entire study population was 7.57+/-2.5 mg/dl. Similar 
linear progression of increase in uric acid levels were noted in the hyperuricemia sub 
group also. ANOVA test was utilized in the analysis and the values were statistically 
highly significant. 
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Table 21 : Mean serum acid in hyperuricemics of various Killip classes 
Killip Class 
of the 
individual 
 Number of 
hyperuricemics   
          (n) Mean Std. Deviation Std. Error 
I 5 7.06 0.43 0.19 
II 28 7.71 0.64 0.12 
III 17 9.71 0.88 0.21 
IV 9 12.46 0.35 0.12 
Total 59 8.96 1.88 0.24 
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 
181.327 3 60.442 132.874 .0005 
Within 
Groups 
25.019 55 .455     
Total 206.345 58       
 
 
Chart 15 : Mean Mean serum acid in hyperuricemics of various Killip classes 
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11. SERUM URIC ACID LEVELS WITH GENDER CORRELATION 
There was no correlation serum uric acid in various age groups in either genders  
Table 22 ; Correlation of serum uric acid ranges in male and female 
  Serum Uric acid level (mg/dl) 
Total   3.1 - 5.0 5.1 - 7.0 7.1 - 9.0 > 9 
Sex Female 5 16 7 6 34 
Male 6 17 25 18 66 
Total 11 33 32 24 100 
 
Chart16 ; Correlation of serum uric acid ranges in male and female 
 
χ 2 test was applied for analysis and p values was 0.082 and was not statistically 
significant. 
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12. HYPERURICEMIA STATUS and GENDER DISTRIBUTION 
50 % of the females in the study population had hyperuricemia defined as serum uric 
acid levels more than 6 mg/dl. 63.6% of the males in the study population had 
hyperuricemia defined as serum uric acid levels more than 7mg/dl.  The chi square 
test was applied and p value was 0.189 and is not statistically significant. 
Table 23 : Gender and serum uric acid distribution 
  Serum Uric acid levels 
Total   Normal Hyperuricemic 
Sex Female 17 17 34 
Male 24 42 66 
Total 41 59 100 
 
Chart 17 : Gender and serum uric acid distribution 
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13. DIABETES AND URIC ACID 
There were 42 individuals with type 2 diabetes mellitus in the study group and the 
proportion of Hyperuricemics noted in the diabetic sub group was 50%. χ2 value was 
2.425 and p value 0.119. This is not statistically significant 
Table 24 : Distribution of serum uric acid levels in diabetics and non diabetics 
  Serum Uric acid level 
Total   Normal Hyperuricemic 
DIABETES No 20 38 58 
Yes 21 21 42 
Total 41 59 100 
 
Chart 18 Distribution of serum uric acid levels in diabetics and non diabetics 
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14. HYPERTENSION AND URIC ACID 
57 patients were hypertensives and 43 patients were non hypertensives. The 
incidence of Hyperuricemia in hypertensives was 73%.  On applying χ2 test, the p 
value was 0.001 indicating that the association has high statistical significance.  
Table 25 : Distribution of serum uric acid levels in HT and Non HTives 
 
  serum uric acid 
Total   Normal Hyperuricemia 
HTN No 26 17 43 
Yes 15 42 57 
Total 41 59 100 
 
Chart 19  : Distribution of serum uric acid levels in HT and Non HTives 
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15. SMOKING and URIC ACID  
47 out of 100 patients were smokers. 35 of them had Hyperuricemia (74.47%). There 
is a significant association between smoking and Hyperuricemia (p value 0.003). 
Table 26 : Distribution of serum uric acid levels in smokers and non smokers 
  Serum uric acid 
Total   Normal Hyperuricemic 
SMOKING No 29 24 53 
Yes 12 35 47 
Total 41 59 100 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson 
Chi-
Square 
8.771a 1 .003 
 
Chart 20 : Distribution of serum uric acid levels in smokers and non smokers 
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16. SERUM CHOLESTEROL with URIC ACID 
33 out of the 100 patients had hypercholesterolemia. 21 out of the 33 dyslipidemic 
subgroup had Hyperuricemia (63.6%) but the association is not statistically 
significant. ( p value 0.508) 
Table 27 : Distribution of serum uric acid levels in dyslipidemics and normal subjects 
 
  Serum uric acid 
Total   Normal Hyper uricemic 
Cholesterol 
range 
< 240 29 38 67 
≥240 12 21 33 
Total 41 59 100 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson 
Chi-
Square 
.438a 1 .508 
 
Chart 21: Distribution of serum uric acid levels in dyslipidemics and normal subjects 
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17. URIC ACID and PRIOR CEREBRO VASCULAR DISEASE 
12 out of the 100 cases had a past history of cerebro vascular accident. 11 out of the 
12 cases (91.67%) had Hyperuricemia. The association between Hyperuricemia and 
cerebrovascular disease was found to be statistically significant. (p value 0.025) 
Table 28 :  Distribution of serum uric acid levels in subjects with prior CVA 
  Serum Uric Acid status 
Total   Normal Hyperuricemic 
CVA No 40 48 88 
Yes 1 11 12 
Total 41 59 100 
 
Chart 22 :  Distribution of serum uric acid levels in subjects with prior CVA 
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18. HYPERURICEMIA and HEART BLOCKS 
15 out of the 100 cases of myocardial infarction had heart blocks. 14 out of the 15 
cases were noted to have Hyperuricemia (93.34%). Significant association was noted 
between incidence of heart blocks and Hyperuricemia (p value 0.003). 
Table 29 :  Distribution of serum uric acid levels in subjects with heart block 
  Uricemia status 
Total   Normal Hyperuricemic 
Heart 
Block 
No 40 45 85 
Yes 1 14 15 
Total 41 59 100 
 
Chart 23 :  Distribution of serum uric acid levels in subjects with heart block 
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19. HYPERURICEMIA AND TYPE OF MYOCARDIAL INFARCTION 
Out of the 59 cases who had hyper uricemia, 41 cases had ST elevation MI and 18 
cases had Non ST elevation MI. There was a statistically significant association 
between Hyperuricemia and STEMI ( p value <0.005). ie. 74.5% of subjects with 
STEMI had Hyperuricemia whereas it is only 40% in subjects with NSTEMI. 
Table 30 : Hyperuricemia status in STEMI and NSTEMI 
TYPE OF MI Hyperuricemia cases 
(n) 
Total Cases Percentage 
(n%) 
STEMI 41 55 74.5% 
NSTEMI 18 45 40% 
  Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 12.210a 1 .0005 
 
Chart 24 : Hyperuricemia status in STEMI and NSTEMI 
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20. MYOCARDIAL INFARCTION LOCATIONS AND SERUM URIC ACID 
Out of the 100 cases, 27 cases had antero-septal wall MI, 44 cases had anterior wall 
myocardial infarction. 25 cases were inferior wall MI and 3 cases suffered from 
infero posterior wall MI with 1 case of inferoposterior all with right ventricular MI.  
Hyperuricemia was noted in 17 out of 27 cases of anteroseptal MI (63%), 28 out of 
44 cases of anterior all MI (63.7%), 8 out of 25 cases of inferior wall MI (32%) and 
3 out of 4 cases of inferoposterior with right ventricular MI (75%). The net incidence 
of Hyperuricemia in inferior wall related myocardial infarction was 28.2%.(11 out 
of 29 cases). The association of higher serum uric acid levels in majority of anterior wall 
myocardial infarction cases was not found to have statistic significance (p value 0.162) 
Table 31 : distribution of uric acid in various MI 
  Location of 
infarction serum uric acid (mg/dl) 
Total 
  
 3.1 - 5.0 5.1 - 7.0 7.1 - 9.0 > 9 
 AS 2 8 9 8 27 
AW 5 11 17 11 44 
IW 4 13 6 2 25 
IW+PW 0 0 0 1 1 
IW+PW+RV 0 1 0 2 3 
      
Total 11 33 32 24 100 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson 
Chi-
Square 
20.264a 15 .162 
Likelihood 
Ratio 
20.078 15 .169 
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Chart 25 : Distribution of MI Locations in study population 
 
Chart 26 : Distribution of Hyperuricemia in various MI subtypes 
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Chart 27 : Distribution of serum uric acid in various MI subtypes 
 
Higher serum uric acid levels were seen in cases of anterior wall and anteroseptal 
wall myocardial infarction cases as compared to inferior wall and inferoposterior 
wall myocardial infarction cases and the association did not have statistical 
significance. The number of inferoposterior wall myocardial infarction cases were 
less as compared to the anterior wall MI cases. Hence significant analysis could not 
be made. 
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21. SERUM URIC ACID and TYPE OF MI 
The overall proportion of Hyperuricemia was more in subgroups with STEMI and 
NSTEMI and the association was statistically significant. 
Table 32 : Serum Uric acid distribution in STEMI and NSTEMI 
  serum uric acid (mg/dl) 
Total   3.1 - 5.0 5.1 - 7.0 7.1 - 9.0 > 9.0 
MI Type NSTEMI 8 23 12 2 45 
STEMI 3 10 20 22 55 
Total 11 33 32 24 100 
[ 
[[ 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson 
Chi-
Square 
25.314a 3 .0005 
Likelihood 
Ratio 
28.144 3 .000 
 
Chart 28 : Serum Uric acid distribution in STEMI and NSTEMI 
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22. URIC ACID and TIMI SCORE 
The mean TIMI score in hyperuricemic subjects in NSTEMI cases was 4.89 ± 0.9 
and 7.56±2.5 in cases of STEMI. 
 
 NSTEMI ( max score 7) STEMI ( max score 13) 
Mean TIMI Score 4.89 ± 0.9 7.56 ± 2.5 
 
 
Chart 29 : Mean TIMI scores in hyperuricemia 
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23. TIMI score in NSTEMI and SERUM URIC ACID 
The mean TIMI score in NSTEMI subgroup with normal uric acid levels were 3.89 
whereas it is 4.89 in the subgroup of NSTEMI with Hyperuricemia. The t test was 
applied for the 2 independent variables and the result was statistically 
significant. ( p value 0.0005) 
Table 33 : Serum uric acid and TIMI score in NSTEMI 
Serum Uric acid status N Mean 
Std. 
Deviation 
Std. 
Erro 
TIMI 
SCORE 
Normal 27 3.89 0.8 0.15 
Hyperuricemic 18 4.89 0.9 0.21 
 
Chart 30 : Serum uric acid and TIMI score in NSTEMI 
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24. TIMI score in STEMI and SERUM URIC ACID 
The mean TIMI score in STEMI subgroup with normal uric acid levels were 
5.64±2.3 whereas it was 7.56±2.5 in the subgroup of STEMI with Hyperuricemia. 
The mean TIMI score was higher in the Hyperuricemia subgroup in STEMI.  The t 
test was applied for the 2 independent variables and the result was statistically 
significant. ( p value 0.0016) 
Table 34 : Serum uric acid and TIMI score in STEMI 
Serum uric acid status N Mean 
Std. 
Deviation 
Std. 
Error 
TIMI 
SCORE 
Normal 14 5.64 2.3 0.6 
Hyperuricemic 41 7.56 2.5 0.4 
 
 
Chart 31 : Serum uric acid and TIMI score in STEMI 
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25. MEAN SERUM URIC ACID and TIMI SCORE in NSTEMI 
As the graph depicts, a linear increase in mean serum uric acid levels were noted in 
patients with higher TIMI scores in NSTEMI. 
Table 35 : Serum uric acid distribution for TIMI score in NSTEMI 
 Serum uric acid (mg/dl) 
TIMI 
Score N Mean Std. Deviation 
3 10 4.83 0.85 
4 17 6.13 1.13 
5 14 6.99 1.32 
6 3 7.43 0.35 
7 1 7.80 0 
Total 45 6.23 1.39 
 
Chart 32 : Serum uric acid distribution for TIMI score in NSTEMI 
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26. MEAN SERUM URIC ACID LEVEL and TIMI score in STEMI 
Linear increase in mean serum uric acid is seen in STEMI also 
Table 36 : Serum uric acid distribution for TIMI score in STEMI 
 
 Serum uric acid levels (mg/dl) 
TIMI Score N Mean Std. Deviation 
3 2 5.35 0.49 
4 4 5.70 1.03 
5 13 8.20 1.38 
6 8 8.23 2.61 
7 8 8.28 1.99 
8 7 10.70 1.90 
9 4 7.87 1.78 
11 5 10.68 1.51 
12 1 12.40  
13 3 10.70 2.98 
Total 55 8.67 2.36 
  
Chart 33 : Serum uric acid distribution for TIMI score in STEMI 
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27. TIMI SCORE and HYPERURICEMIA 
The mean TIMI score of all hyperuricemic individuals was 6.75 as compared to the 
sub group with normal serum uric acid levels whose mean TIMI score was 6.75. 
paired t test was utilized in the statistical analysis and the association is highly 
significant ( p value 0.0005) 
Table 37 : Serum uric acid distribution vs TIMI score in general (all MI) 
Uric acid status Number of 
subjects 
Mean TIMI score Standard 
Deviation 
Normal 41 4.49 1.70 
Hyperuricemia 59 6.75 2.48 
 
Chart 34 : Serum uric acid distribution vs TIMI score in general (all MI) 
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COMPARISON OF TIMI SCORES 
The mean TIMI score are higher in both subgroups of MI ( STEMI and NSTEMI) . 
The average TIMI score in general is also higher in hyperuricemic subjects. 
 Table 38: Comparison of TIMI score in hyper and normouremics 
 
 Normouricemia Hyperuricemia 
TIMI in 
NSTEMI 
3.89 4.89 
Total 
average 
4.49 6.75 
TIMI in 
STEMI 
5.64 7.56 
 
Chart 35: Comparison of TIMI score in hyper and normouricemics 
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28. GRACE SCORE and SERUM URIC ACID 
The grace score was calculated for all patients for their in-hospital risk of mortality. 
The mean risk of in-hospital mortality in patients with normal uric acid levels (n=41) 
was 4% whereas it was found to be 13.44% in the 59 subjects with elevated serum 
uric acid levels. There was a statistically highly significant association between 
serum uric acid levels and the in hospital risk of mortality as calculated by the 
GRACE score. (p value 0.0005)  
Table 39 : mean GRACE score vs Serum uric acid levels 
Serum uric acid status Number of subjects Mean GRACE IP risk 
NORMAL 41 4.0% 
HYPERURICEMIA 59 13.44% 
 
Chart 36 : mean GRACE score vs Serum uric acid levels 
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25. SERUM URIC ACID and EJECTION FRACTION 
Serum uric acid levels were correlated with the ejection fraction done by 2-D 
echocardiogram. There was an inverse relationship between serum uric acid levels and the 
ejection fraction. Higher serum uric acid levels correlated with lower ejection fractions. 
The result was statistically significant ( p value 0.0005) 
Table 40 : Serum uric acid correlation with Ejection Fraction % 
  Serum uric acid 
  Normal Hyperuricemic 
Ejection 
Fraction 
≤ 25     % 0 5 
26 – 30 % 1 10 
31 – 35 % 0 12 
36 – 40 % 1 16 
41 – 45 % 14 15 
46 – 50 % 18 0 
51 – 55 % 7 1 
Total 41 59 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson 
Chi-
Square 
58.798a 6 .0005 
 
Chart 37 : Serum uric acid correlation with Ejection Fraction % 
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There were 5 subjects in the study population with ejection fraction less than 25%. 
All patients had serum uric acid more than 9 mg%. All the 11 patients with ejection 
fraction between 25 – 30% also had serum uric acid more than 9 mg%. 
The association is statistically significant (p value 0.0005) 
Table 41 : Serum uric acid range vs Ejection fraction % 
    Serum uric acid (mg/dl) 
Total 
    3.1 - 5.0 5.1 - 7.0 7.1 - 9.0 > 9 
Ejection 
fraction 
range 
<= 25 0 0 0 5 5 
26 - 30 0 0 0 11 11 
31 - 35 0 0 5 7 12 
36 - 40 0 3 13 1 17 
41 - 45 2 14 13 0 29 
46 - 50 5 12 1 0 18 
51 - 55 4 4 0 0 8 
Total 11 33 32 24 100 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson 
Chi-
Square 
124.337a 18 .0005 
 
Chart 38 : Serum uric acid range vs Ejection fraction % 
 
0
5
10
15
<= 25 26 - 30 31 - 35 36 - 40 41 - 45 46 - 50 51 - 55
0 0 0 0
2
5
4
0 0 0
3
14
12
4
0 0
5
13 13
1
0
5
11
7
1 0 0 0
N
u
m
b
e
r 
o
f 
su
b
je
ct
s
Ejection Fraction and uric acid quartiles
EF with Uric acid range
3.1 - 5.0 5.1 - 7.0 7.1 - 9.0 > 9
95 
 
DISCUSSION 
AGE DISTRIBUTION 
The average age of the present study was 57.16 years, which truly reflects the 
statement that AMI occurs 5-10 years earlier in our population than the western 
population. The age range varied from 34 years to 80 years. Majority of patients 
belonged to the age group between 51-60 years, which was also the age group with 
maximum mortality. However this data was not found to be statistically significant. 
Study in a Japanese group by M Kuzuya et al showed a decline in uric acid levels 
between 30-70 years in males, but a rise in uric acid levels after about 45 years in 
females75,76. 
 
GENDER DISTRIBUTION 
The study included 66% males and 34% females. Male predominance was observed 
in all the age subgroups included in the study. According to Viola Vaccarino et al, 
increased early mortality was seen in women after acute myocardial infarction, 
probably due to their old age; however on controlling the risk factors, females had 
better survival rates than males in the long run83,85. Our study showed no significant 
association between gender and mortality. Similarly there is no significant 
association between elevated uric acid levels and male gender, though the mean uric 
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acid levels were higher in males compared to females. This is in accordance with the 
studies done by Dharma86 et al in Indonesia and Nadkar73 et al. 
 
TROPONIN T AND MORTALITY 
Peter Stubbs et al had come to the conclusion that elevated Troponin T in patients 
with STEMI at the time of admission , increased the risk of subsequent cardiac 
events as compared to those with normal values78. This correlates well with our 
study, in which 100% of the patients who expired, had elevated Troponin T values 
and this was found to statistically highly significant. 
 
HYPERURICEMIA AND MORTALITY 
The proportion of hyperuricemics in the study population was 59%. Out of the 9 
patients who succumbed to death following an acute myocardial infarction, all of 
them were hyperuricemic at presentation. This establishes a strong significant 
association between elevated serum uric acid levels and mortality rates in acute 
coronary syndrome. According to Vladimir Trkulja et al, higher serum uric acid on 
admission was independently associated with thirty day mortality67. The 
Framingham Heart study which compared serum uric acid with the risk for 
cardiovascular mortality, established a strong association between baseline serum 
uric acid levels and coronary artery disease and death. However a causal association 
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could not be established. Considering the inextricable link with diabetes, 
hypertension and dyslipidemia, hyperuricemia could be taken as a marker of risk for 
cardiovascular disease. 
 
ASSOCIATION OF URIC ACID WITH RISK FACTORS 
Nadkar et al and Dharma et al could not find any statistically significant association 
between elevated serum uric acid levels and diabetes mellitus or hypertension. This 
is in contrast to the LIFE study and NHANES study. 
 
[A] DIABETES MELLITUS AND URIC ACID 
42% of the study group were diabetics. No significant association was observed 
between diabetes mellitus and serum uric acid levels(p=0.119). D M Cook et al 
described that uric acid levels were significantly reduced in insulin dependent 
patients, in those on oral antidiabetic agents as well as non diabetic population with 
random glucose leves>10 mmol/L,but such a negative association was not seen in 
our study80,81. 
[B] HYPERTENSION AND URIC ACID 
A recent cohort study in subjects with hypertension established a significant 
association between the two. Our study revealed that the presence of hyperuricemia 
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in hypertensives was 73%, which has high statistical significance and is in 
accordance with the cohort study94. 
 
[C] SMOKING AND URIC ACID 
Studies done previously suggest that uric acid levels are low in smokers due to 
chronic exposure to cigarette smoke, which causes oxidative stress79. However 
significant association was found between smoking and hyperuricemia in this 
study(p=0.003). The prevalence of hyperuricemia in smokers in our study was found 
to be 74.47%. 
 
[D} DYSLIPIDEMIA AND URIC ACID 
Studies done by Li Chen et al showed a positive correlation between triglyceride 
level and hyperuricemia71. However no statistically significant association could be 
elicited between dyslipidemia and hyperuricemia in this study. The proportion of 
hyperuricemics in the dyslipidemic subgroup was 63.6%. 
 
[E] URIC ACID AND PRIOR CEREBROVASCULAR DISEASE 
91.67% of patients with a prior history of cerebrovascular event, had elevated serum 
uric acid levels. The association between the two is statistically significant with a  p 
value of  0.025. According to Ioana Mozos et al, the mortality was higher in stroke 
patients with hyperuricemia90. This association was not seen in our study. 
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URIC ACID AND HEART BLOCKS 
In a study done by Laurens P et al in 158 patients with isotopic pacemaker 
implantations, he described that the frequency of hyperuricemia is more in such 
patients91. 93.94% of the patients with heart blocks following acute myocardial 
infarction in our study, were found to be hyperuricemic. Hence significant 
association exists between heart blocks and hyperuricemia(p=0.003). 
 
URIC ACID AND MI- TYPES AND LOCATIONS 
The proportion of STEMI was found to be higher in patients with hyperuricemia 
than NSTEMI in the study. This association is highly significant. Higher serum uric 
acid levels were seen in cases of anterior wall and anteroseptal wall MI, when 
compared to inferior and inferoposterior wall MI. However no association could be 
established between the location of myocardial infarction and uric acid levels, owing 
to lesser number of inferior and inferoposterior wall MI cases. 
 
URIC ACID AND TIMI SCORE 
The mean TIMI score, which is a prognostication score used for risk stratification, 
was found to be higher in patients with elevated serum uric acid levels in comparison 
with those with normal uric acid levels, in both STEMI as well as NSTEMI patients. 
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There exists a linear relation between the mean serum uric acid levels and TIMI 
scores. 
 
URIC ACID AND KILLIP CLASS 
The mean serum uric acid level has a linear relation with killip class, indicating that 
serum uric acid levels correlate with the severity of myocardial infarction as assessed 
by killip classification. 24 patients in the study group had uric acid levels more than 
9mg/dl and 91.96% belonged to killip classes 3 and 4. This is a significant 
association. Similar results were brought out by Trkulja et al and Li Chen et al in 
their studies, thereby highlighting the prognostic significance of uric acid in 
myocardial infarction71. 
Mortality in this study was 9% and all the subjects had serum uric acid >9mg/dl. 
Nadkar et al reported hyperuricemia in 100% of the deaths that occurred in their 
study73. SUA levels > 7mg/dl was the strongest independent predictor of mortality 
according to Dharma et al.  
 
GRACE SCORE AND URIC ACID 
The association between serum uric acid levels and in-hospital risk of mortality, as 
calculated by GRACE score is highly significant with a p value of 0.0005. Subjects 
with hyperuricemia had a 9.44% increase in risk of death during hospital stay during 
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the acute period, which makes SUA a relatively reliable predictor of short term 
mortality. 
 
URIC ACID AND EJECTION FRACTION 
LV dysfunction is an important prognostic indicator in myocardial infarction. In our 
study, there exists an inverse relation between serum uric acid levels and ejection 
fraction. 16 subjects in the study population had ejection fraction <30%, all of whom 
had serum uric acid> 9mg/dl. 66.67% of the subjects that expired during the study 
period were included in this subgroup. This is further proof that serum uric acid can 
be used to predict mortality and severity of left ventricular dysfunction and heart 
failure. This is supported by the study done by Li Chen71 et al. 
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CONCLUSIONS 
1. Serum uric acid levels are elevated in patients with acute myocardial infarction. 
2. There is a strong correlation between serum uric acid levels at the time of 
admission and in-hospital and short-term mortality in patients with acute myocardial 
infarction. Patients with elevated SUA levels had higher Killip class in STEMI and 
higher mortality rates and Major adverse cardiovascular outcomes. 
3. Patients with elevated Troponin T had higher mortality. 
4. Elevated serum uric acid had positive correlation with systemic hypertension and 
smoking. 
5. Patients with elevated serum uric acid levels had higher TIMI scores and 10% 
higher risk of in-hospital death as calculated by GRACE score. 
6. Patients with elevated serum uric acid had lower ejection fraction during 
echocardiographic study. 
7. Uric acid may be considered as  a reliable , noninvasive easily available and cheap 
independent prognostic marker in predicting the severity of myocardial infarction 
along with short term outcome. 
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LIMITATIONS OF THE STUDY 
1. The percentage of NSTEMI patients included in the study were more 
compared to the general statistics as suggested by other landmark studies, 
which indirectly influenced the mortality rates. 
2. The proportion of females included in the study was limited and hence the 
result cannot be extrapolated into the general population. 
3. The follow up period was less than 30 days thereby limiting the study to 
understanding only the short term outcomes. Long term mortality and 
morbidity data could not be assessed. Whether serum uric acid could predict 
long term outcome indicators of mortality and morbidity could not be found 
out. 
4. The study being conducted in a tertiary care center, many of the patients 
presented as referred cases with a variety of complications of AMI, thereby 
increasing the number of major adverse cardiac outcomes.  
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SUMMARY 
This study was undertaken to evaluate whether serum uric acid could prove to be a 
useful marker in predicting the severity of  acute myocardial infarction, being a 
cheap, easily available and simple investigation ,which is crucial for a developing 
nation like ours. The SUA levels of patients with new onset myocardial infarction 
were measured and correlated with the severity of involvement using prognostic 
scores such as Killip, TIMI and GRACE as well as ejection fraction and other 
complications.. Other co-existing risk factors like diabetes mellitus, systemic 
hypertension, smoking, dyslipidemia, prior CVA were evaluated for a possible 
correlation. 
In our study of 100 subjects with AMI, 55 had STEMI and 45 had NSTEMI.  8 
patients with STEMI and 1 patient with NSTEMI succumbed to death during the 
study period. Patients with high Troponin T values, high serum uric acid levels  had 
higher mortality rates and belonged to higher Killip class. Positive association was 
found between hyperuricemia and smoking, hypertension and heart blocks. Out of 
the patients with uric acid >9mg/dl, 100% had an ejection fraction < 30%, and 91.6% 
belonged to Killip classes III and IV which was highly significant statistically. 
Hyperuricemic patients had higher TIMI scores in both STEMI and NSTEMI and 
also had 9.44% higher risk of in-hospital mortality, as calculated by GRACE score. 
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High serum uric acid levels correctly predicted the mortality and in-hospital major 
adverse cardiac events, and proved to be a successful and useful prognostic predictor 
of short term survival and complications in acute myocardial infarction. 
 
SCOPE FOR FUTURE RESEARCH 
Uric acid is an old molecule with new applications. It is an antioxidant which 
paradoxically has a pro-oxidant action in latter stages of atherosclerosis. 
Hyperuricemia reduces the production of nitric oxide in vascular endothelium and 
cause no-reflow during reperfusion. The Xanthine oxidase activity and synthesis of 
uric acid is disproportionately accelerated in ischaemic conditions. Hence the 
therapeutic role of inhibiting Xanthine oxidase needs to be studied. Studies have 
demonstrated uric acid reducing action of Atorvastatin and Losartan. But large trials 
need to be undertaken to establish a definitive role for these drugs in the future. Some 
theories claim that uric acid is predominantly released from the necrosed 
myocardium in AMI, leading to its increased levels. Whether it can serve as a marker 
of the extent of myocardial necrosis needs to be proven by future studies. 
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PROFORMA 
NAME  : 
AGE/SEX :   
ADDRESS : 
 
I.P NO:                                     D.O.A:     D.O.D: 
 
 COMPLAINTS OF THE PATIENT: 
 1.CHEST PAIN               :  YES / NO                           
2. DURATION OF CHEST PAIN                             
3. BREATHLESSNESS         : YES/ NO 
4. PALPITATION   : YES/ NO 
5. SYNCOPE                      : YES/ NO 
6. SWEATING    : YES/ NO 
HISTORY IN DETAIL: 
 
 
HISTORY OF PAST ILLNESS: 
CAD    YES/NO 
DM    YES/NO 
SHTN    YES/NO 
FAMILY HISTORY  YES/NO 
PRIOR CVA   YES/NO 
Usage of Aspirin  YES/NO 
 
PERSONAL HISTORY: 
SMOKING AND DURATION:  
CLINICAL  EXAMINATION : 
VITAL SIGNS 
BP PULSE RATE RESPIRATORY 
RATE 
TEMPERATURE 
    
 
GENERAL EXAMINATION : 
 
 
SYSTEMIC EXAMINATION:   
1. CARDIOVASCULAR SYSTEM         : 
 
2.RESPIRATORY SYSTEM                 : 
 
3. PER ABDOMEN                          : 
 
4. CENTRAL NERVOUS SYSTEM       : 
 
INVESTIGATIONS : 
ECG 
RFT      S.CREATININE   mg/dl  
TOTAL CHOLESTEROL   mg/dl 
S. TAG      mg/dl 
Random blood sugar   mg/dl 
TROPONIN   POSITIVE/NEGATIVE 
    LOW/HIGH 
 
ECHOCARDIOGRAPHIC FINDINGS: 
 
LVEF               % 
RV DYSFUNCTION   YES/NO 
CONCENTRIC LVH   YES/NO 
 
 DAY 0 DAY 3 
S. URIC ACID LEVEL 
(mg/dl) 
  
 
DIAGNOSIS    : 
DURATION OF HOSPITAL STAY : 
FINAL OUTCOME    :  
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1 SARASWATHY 77 F 6 Y N N N Y N N Y 2 HYPER 86 245 LOW IW STEMI N 1 7 4.3 5.4 5.6 50 Y N N 5 N 
2 CHINNAN 45 M 5 Y N Y Y N N N N 2 NORMAL 75 232 LOW AW STEMI N 2 6 2.9 4.3 4.1 41 N N N 5 N 
3 ANBARASI 52 F 4 Y N N Y N N N N 1 NORMAL 87 182 HIGH AW STEMI N 1 3 2.1 5.7 4.9 53 N N N 5 N 
4 JEYMUNISHA 55 F 2 Y Y Y Y Y N Y N 4 HYPER 78 278 HIGH AS STEMI Y 3 5 6.2 9.6 9.3 33 Y N LBBB 8 N 
5 SATHYANARAYAN 70 M 3 Y Y Y N Y Y N Y 3 HYPER 77 210 HIGH AW NSTEMI N 2 7 3.3 7.8 7.8 38 Y N N 5 N 
6 CHINNAKANNAN 70 M 6 Y Y N Y N Y N N 3 HYPO 106 233 HIGH AW STEMI Y 4 13 50 12.9   34 N N qRBBB  2 Y 
7 VALLINAYAKI 65 F 2 Y N N N N N N N 0 NORMAL 86 176 LOW AW NSTEMI N 1 4 3.5 6.2 6.5 54 N N N 5 N 
8 MUNUSAMY 89 M 2.5 Y Y Y N Y Y N N 3 HYPER 72 274 HIGH AS STEMI Y 3 7 30 11.2 10.3 27 Y N LBBB 8 N 
9 ANSARI 46 F 4 Y N Y Y N N Y N 3 NORMAL 79 342 LOW IW NSTEMI N 1 5 1.1 3 5.4 45 N N N 5 N 
10 BABU 36 M 4 Y N N Y N N N N 2 NORMAL 75 302 HIGH AW STEMI N 2 6 1.5 7.8 7.2 42 N N N 5 N 
11 SHANTHI 45 F 2.5 Y N Y N Y N Y N 2 HYPER 81 160 LOW AW NSTEMI N 1 3 1.5 3.4 3.3 55 N N N 5 N 
12 PALANIYAMMAL 55 F 6 Y N N N Y N Y N 2 HYPER 86 190 LOW IW NSTEMI N 2 4 2.7 7.1 6.4 40 N N N 5 N 
13 RAVINAMMAL 65 F 5 Y Y Y N Y N N Y 2 HYPER 89 212 HIGH AS NSTEMI Y 2 6 4.9 7.8 7.8 38 Y N LBBB 8 N 
14 CHELLAPAPPA 45 F 3 Y N N Y N N N N 1 NORMAL 92 178 LOW AS NSTEMI N 1 3 1.8 4.5 4.6 55 N N N 5 N 
15 MARIYAPPAN 52 M 6 Y N Y N Y Y N N 2 HYPER 70 190 LOW AW STEMI Y 2 5 2.1 8.1 7.8 42 Y N LBBB 7 N 
16 ESWARAN 45 M 5 Y N N Y N N N N 2 NORMAL 86 231 HIGH AW STEMI N 1 4 1.6 6.9 6.5 47 N N N 5 N 
17 BANGARUSAMY 75 M 8 Y N Y Y N N N N 2 NORMAL 68 199 HIGH IW NSTEMI N 1 5 5.6 7.7 7.1 44 N N N 5 N 
18 GANESHAN 62 M 9 Y N Y Y N N N N 1 NORMAL 76 170 LOW IW NSTEMI N 1 4 3 4.1 3.9 47 N N N 5 N 
19 NAGAMMAL 59 F 5 Y Y Y N Y N Y Y 4 HYPER 89 222 HIGH IW STEMI N 3 11 60 10.1 9.8 32 Y N N 9 Y 
20 PARVATHI 56 F 4 Y N N N Y N N N 1 NORMAL 76 160 LOW PW+RV NSTEMI N 1 3 2.4 4.9 5.1 50 Y Y N 5 N 
21 RAJESWARAN 68 M 6 Y N N N Y Y Y N 3 HYPER 77 188 HIGH AS STEMI N 3 8 9.9 8.9 7.1 42 Y N N 8 N 
22 KANAGAMMAL 78 F 7 Y N N N Y N N N 2 HYPER 95 210 LOW AW STEMI N 1 9 4.9 5.9 5.1 43 N N N 5 N 
23 NARAYANAN 68 M 3 Y Y Y N Y Y N Y 2 HYPER 94 180 HIGH AW STEMI Y 4 11 18 12.1 10.2 18 Y N LBBB 12 N 
24 PALANIYAMMAL 65 F 8 Y Y Y N Y N N N 2 HYPO 94 223 HIGH AW NSTEMI N 2 5 34 9.1 9 28 N N 
PERICARDITI
S 
12 Y 
25 DEVAKANNI 70 F 4 N Y Y Y N N N N 2 NORMAL 96 289 LOW IW NSTEMI Y 2 5 11 7.2 6.5 44 N N LBBB 5 N 
26 SRINIVASAN 53 M 5 Y N Y N Y Y N N 2 HYPER 84 170 LOW AS STEMI N 2 6 2.5 7.7 7 41 N N N 5 N 
27 IYAMMAL 62 F 9 Y N Y Y Y N Y N 4 HYPER 78 201 HIGH AS NSTEMI N 1 5 1.7 7 7.1 45 Y N N 5 N 
28 ARULAPPAN 52 M 4 Y N N Y N N N N 1 NORMAL 84 190 LOW AW NSTEMI N 1 3 2 4.1 3.9 51 N N N 5 N 
29 KATHURAMALAI 52 M 6 Y N Y Y Y Y N N 4 HYPER 83 245 HIGH IW STEMI Y 2 5 2.8 8.9 9.4 38 Y N RBBB 7 N 
30 NATARAJ 69 M 7 Y Y N N Y Y Y N 3 HYPO 91 189 HIGH IW+PW+R STEMI Y 4 12 78 12.4 12.2 22 Y Y CHB 3 Y 
V 
31 SHAJAHAN 41 M 4 Y Y Y N Y Y N N 3 HYPER 76 216 HIGH AW NSTEMI N 2 5 2.3 8.5 7.2 44 N N N 5 N 
32 TAMILSEVAN 70 M 6 Y N Y N N Y N N 2 NORMAL 77 199 LOW AW NSTEMI N 1 5 4.9 5.5 5.2 48 N N N 5 N 
33 ANBARASI 44 F 4 Y N N Y N N N N 2 NORMAL 70 234 LOW AW STEMI N 1 3 1.1 5 4.9 50 N N N 5 N 
34 ARJUNAN 55 M 5 Y N N Y N N Y N 2 HYPO 87 177 HIGH IW STEMI N 1 4 13 4.5 4.3 55 N N N 5 N 
35 BALAKRISHNAN 46 M 3 Y Y Y Y N N N N 1 HYPO 88 190 LOW IW+PW STEMI Y 3 6 29 10.8 10.5 33 Y N LBBB 10 N 
36 MALAR 51 F 5 Y N Y N Y N N N 2 HYPER 88 245 HIGH AW STEMI N 2 6 2.8 6.5 6 39 N N N 5 N 
37 PALANIMUTHU 78 M 4 Y N Y N Y Y N N 3 HYPER 96 240 LOW AW STEMI N 2 13 9.5 7.3 7 35 Y N N 5 N 
38 LOGANATHAN 58 M 5 Y Y N N Y Y N N 3 HYPO 94 221 HIGH AW STEMI Y 3 11 48 9.9   27 Y Y CHB+VSR 1* Y 
39 SITHAN 60 M 8 Y N N N Y Y N N 2 HYPER 92 179 HIGH AS NSTEMI N 2 4 3.8 7.8 5.2 40 Y N N 5 N 
40 CHINNAPAMANI 62 M 4 N N Y Y N N N N 2 NORMAL 83 226 HIGH AS NSTEMI N 1 4 3.5 6.5 6 46 N N N 5 N 
41 SELVAM  42 M 1 Y N N N Y Y Y N 4 HYPER 75 270 LOW AW STEMI Y 2 6 6.2 8.4 6.9 40 N N LBBB 5 N 
42 PURMANGATHAN 65 M 7 Y Y N N Y Y N N 3 NORMAL 86 199 HIGH AW STEMI N 3 8 16 10 10.8 30 Y N N 7 Y 
43 PERIYANNAN 68 M 5 Y N Y N Y Y N N 2 HYPER 84 160 LOW IW NSTEMI N 1 5 2.5 5.6 5.5 48 Y N N 5 N 
44 MADHAIYAN 53 M 5 Y N Y N Y Y Y N 3 HYPER 73 180 LOW IW NSTEMI N 1 4 1.1 5.2 5 50 N N N 5 N 
45 KRISHNAN 45 M 3 Y N N N Y Y Y N 4 HYPER 76 256 LOW AS STEMI N 1 4 1 5.3 4.9 54 N N N 5 N 
46 PALANIYAMMAL 65 F 8 Y N N N Y N N N 2 HYPER 87 227 HIGH AW STEMI N 2 7 5.8 7.8 8.3 43 N N N 5 N 
47 ANGUMANI 61 F 6 Y Y Y Y N N N Y 2 NORMAL 82 212 HIGH AW NSTEMI N 3 5 7.7 9.1 9 35 Y N N 8 N 
48 SENTHILKUMAR 47 M 4 Y Y Y N Y Y N N 3 HYPER 
11
0 
267 HIGH AW STEMI N 4 8 16 12.8 12.7 20 Y N N 10 N 
49 CHINNAPONNU 80 F 7 Y Y Y Y N N Y Y 3 HYPER 80 210 HIGH AW STEMI N 4 11 43 11.9 12.4 17 Y N VT 10 Y 
50 MADESHWARAN 54 M 3 Y N Y N Y Y N N 2 HYPER 
10
0 
190 LOW IW NSTEMI N 1 3 1.7 3.9 4.2 50 N N N 5 N 
51 BALAMURUGAN 50 M 5 Y N N Y N N N N 2 NORMAL 90 290 LOW IW NSTEMI N 1 4 2.1 4.5 5.1 45 N N N 5 N 
52 PRAKASH 40 M 5 Y N N N Y Y N N 3 HYPER 
11
0 
210 HIGH AW STEMI N 2 8 2.4 7.9 7.5 35 Y N N 5 N 
53 ALLIMUTHU 55 M 10 Y N Y Y N N N N 1 NORMAL 90 159 LOW AW NSTEMI N 2 4 5.2 7 6.9 40 N N N 5 N 
54 SUBRAMANI 67 M 4 Y Y N N N Y N Y 1 NORMAL 
11
0 
187 HIGH AW STEMI N 3 9 25 7.9 8 34 N N N 7 N 
55 ALAMELU 50 F 6 Y N Y Y N N Y N 2 NORMAL 89 190 LOW IW NSTEMI N 1 4 1.9 5.5 5.1 44 N N N 5 N 
56 MANICKAM 65 M 3 Y Y Y N Y Y N N 2 HYPO 69 166 HIGH AS STEMI Y 3 11 19 8.9 7.8 37 Y N LBBB 9 N 
57 ANJALAI 60 F 6 Y N N Y N N N N 2 NORMAL 73 230 LOW AS NSTEMI N 2 4 5.7 4.3 5 43 N N N 5 N 
58 ELUMALAI 35 M 5 Y N N Y N N N N 2 NORMAL 75 201 HIGH AS NSTEMI N 1 4 0.8 5.9 5.3 47 N N N 5 N 
59 VENGATESWARI 55 F 2 Y N N N N N Y N 1 NORMAL 78 190 LOW AW NSTEMI N 1 4 2.3 6.7 6.9 45 N N N 5 N 
60 RAJENDRAN 55 M 2 Y N N N Y Y N N 3 HYPER 98 245 HIGH AS STEMI N 2 7 3.2 7.9 8 44 N N N 5 N 
61 DHANAM 60 F 1 Y N N Y N N N N 2 NORMAL 79 267 LOW IW STEMI N 1 4 2.7 5.2 6.1 45 N N N 5 N 
62 GURUNADHAN 72 M 4 Y Y Y Y Y Y Y N 5 HYPO 
12
0 
290 HIGH 
IW+PW+R
V 
STEMI N 4 13 85 11.9 11.8 26 Y Y N 12 N 
63 SHAKILA BANU 34 F 4 Y N Y N Y N N N 2 HYPER 98 210 LOW AW STEMI N 1 5 0.6 4.9 5.8 44 N N N 5 N 
64 SUNDARARAJAN 47 M 2 Y N Y N N Y N N 1 NORMAL 82 197 HIGH AW STEMI N 2 5 3.8 7.6 7.1 38 N N N 5 N 
65 CHINNU 49 M 3 Y N N Y N N N N 2 NORMAL 81 230 LOW AW NSTEMI N 1 3 1.9 5.5 5.8 49 N N N 5 N 
66 PATHEELA 47 F 5 Y Y Y N Y N Y N 3 HYPER 74 265 HIGH AS STEMI Y 4 6 6.7 12.6 12.9 28 Y N LBBB 12 N 
67 AMANULLAH 43 M 1 Y N Y Y N N N N 1 NORMAL 83 189 LOW IW NSTEMI N 1 4 1.3 6.1 5.4 48 N N N 5 N 
68 VARADHAMMAL 60 F 4 Y N N N N N Y Y 2 NORMAL 87 230 LOW IW STEMI N 2 5 6.2 7.2 6.9 42 N N N 5 N 
69 THANGAVEL 65 M 4 Y N N N N Y Y N 2 NORMAL 91 167 HIGH AS STEMI N 1 7 4.5 5.7 6.2 45 N N N 5 N 
70 RAJU 60 M 3.5 Y Y N N Y Y N N 3 HYPER 73 296 HIGH AW STEMI N 3 5 6.7 8.6 8.8 34 Y N N 8 N 
71 SUBRAMANI 54 M 2 Y Y Y N N Y N N 2 NORMAL 84 211 HIGH AS STEMI N 3 5 8.7 9.9 9.2 30 N N N 8 N 
72 BABU 53 M 3 Y N N Y N N N N 1 NORMAL 75 130 LOW IW NSTEMI N 1 4 2 6.4 5.8 43 N N N 5 N 
73 PREMA 58 F 5 Y N Y N Y N N N 2 NORMAL 79 278 HIGH AW NSTEMI N 2 4 5.2 6.9 5.2 41 N N N 5 N 
74 SOLAI 59 M 3 Y N Y N Y Y Y N 4 HYPER 87 266 HIGH AS STEMI N 2 6 4.3 7.5 7.4 42 Y N N 5 N 
75 MANICKAM 65 M 2 Y N Y N Y Y N N 3 HYPER 94 284 LOW AW STEMI N 1 7 3.5 7.3 7 47 Y N N 5 N 
76 PAPPATHI 45 F 2.5 Y N Y N Y N Y N 2 HYPER 78 186 HIGH AS NSTEMI N 1 3 0.8 4.9 5.3 49 N N N 5 N 
77 SARAVANAN 49 M 6 Y Y N N Y Y Y N 4 HYPER 
10
4 
289 HIGH AS STEMI Y 3 8 
16.
6 
9.8 9.1 30 N N LBBB+VT 3* Y 
78 ALAMELU 75 F 4 Y N N Y N N Y N 3 NORMAL 74 210 HIGH IW STEMI N 2 9 14 7.4 7.2 40 N N N 5 N 
79 
SUKKARAIYAMMA
L 
45 F 3 Y Y N N N N Y N 1 NORMAL 77 177 LOW AW NSTEMI N 1 3 1.5 4.2 4 50 N N N 5 N 
80 PERUMAL 57 M 2.5 Y Y Y N Y Y N N 3 HYPER 96 263 HIGH AS STEMI N 3 7 8.6 8.9 8.7 33 Y N N 9 N 
81 SYED AMEER 52 M 2 Y N Y N N Y N N 2 NORMAL 85 245 LOW AS NSTEMI N 1 3 2.1 5.3 5.8 55 N N N 5 N 
82 THIYAGARAJAN 62 M 4 Y Y Y N N Y N N 1 NORMAL 84 185 HIGH AW STEMI N 3 5 13 9.6 9.2 34 N N N 8 N 
83 IYADURAI 60 M 3 N N Y Y Y Y Y Y 5 HYPER 76 201 HIGH AW NSTEMI N 2 5 3.2 7.8 7 40 Y N N 5 N 
84 GNANAMMAL 57 F 5 Y N Y Y N N Y N 2 NORMAL 79 168 LOW IW STEMI N 2 5 4.6 6.5 6 44 N N N 5 N 
85 SELVARAJ 50 M 3 Y N Y N Y Y Y N 3 HYPER 82 196 HIGH IW NSTEMI N 1 3 1.1 5.8 5.4 48 Y N N 5 N 
86 CHINNAPONNU 40 F 5 Y Y N Y N N Y N 3 NORMAL 89 231 LOW IW NSTEMI N 2 5 2.5 6.9 5.2 42 N N N 5 N 
87 GOVINDHARAJ 40 M 4 Y N N Y Y N Y N 4 HYPER 76 230 LOW AW STEMI N 2 5 1.2 7.1 7.3 40 N N N 5 N 
88 PALANIYAPPAN 68 M 4.5 Y Y Y N Y Y Y N 4 HYPER 72 213 HIGH AS STEMI N 4 8 22 11.8 12.3 26 Y N N 14 N 
89 VEERAMMAL 72 F 3 Y N Y N N N Y N 1 NORMAL 85 176 LOW AS NSTEMI N 1 5 5.9 5.8 5 41 N N N 5 N 
90 GOPAL 75 M 2 Y N Y Y Y N Y N 4 HYPER 87 256 HIGH AW NSTEMI N 2 6 7.5 6.8 7.4 39 N N N 5 N 
91 RAMESH BABU 52 M 4 Y Y Y N Y Y N N 3 HYPER 89 267 HIGH AS STEMI N 3 5 5.4 9.7 8.1 30 Y N N 9 N 
92 JAGADEESAN 56 M 3 Y Y N Y Y Y Y N 5 HYPER 98 204 HIGH AW STEMI N 3 7 12 10.4 10.8 33 Y N N 3* Y 
93 ARUNACHALAM 65 M 8 Y N N Y N N N N 1 NORMAL 90 158 LOW IW NSTEMI N 1 5 4.5 5.6 5.4 40 N N N 5 N 
94 NARASAPPAN 54 M 6 Y N Y N Y Y N N 3 HYPER 77 234 LOW AS NSTEMI N 1 5 5.9 6.2 6.6 45 N N N 5 N 
95 CHINNASAMY 50 M 5 Y N N Y N N N N 1 NORMAL 84 164 HIGH IW NSTEMI N 2 4 3.7 7.9 7.3 40 N N N 5 N 
96 KANDHAN 56 M 2.5 Y N N Y Y Y Y Y 5 HYPER 83 257 LOW AW NSTEMI N 1 6 1.5 6.9 7.1 42 Y N N 5 N 
97 JAGADEESAN 52 M 7 Y N Y Y Y Y N N 2 HYPER 79 167 HIGH AW STEMI N 2 5 2.7 7.2 7 40 N N N 5 N 
98 GOVINDHRAJ 77 M 6 Y Y N Y Y Y N Y 3 HYPER 83 183 HIGH AS STEMI N 3 9 19 10.2 10.2 30 N N N 8 N 
99 MASJAN 43 M 5 Y Y N N Y Y N N 3 HYPO 78 218 LOW AW STEMI N 4 8 9.3 11.9 12.4 17 Y N N 10 N 
100 MADHU 60 M 4 Y N Y N Y Y Y N 3 HYPER 90 148 LOW IW NSTEMI N 2 4 3.8 4.1 4.3 48 N N N 5 N 
 
